title: Late onset imatinib-induced Stevens-Johnson syndrome.
abstract: Imatinib, a BCR-ABL tyrosine kinase inhibitor, is known to cause mild to moderate cutaneous reactions in up to approximately 20% of patients. It rarely causes severe reactions, such as Stevens-Johnson syndrome, which can be life threatening. Typically, these rashes occur within two months of initiating therapy. We report a case of Stevens-Johnson syndrome induced by imatinib after several years of therapy, but later successfully was treated with nilotinib therapy.
authors.affiliation: Rite Aid, Waterville, ME, USA.
authors.forename: Evan
authors.initials: E
authors.lastname: Bois
authors.affiliation: Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT, USA lisa.holle@uconn.edu.
authors.forename: Lisa M
authors.initials: LM
authors.lastname: Holle
authors.affiliation: Department of Medicine, Division of Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Umar
authors.initials: U
authors.lastname: Farooq
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D013997:Time Factors; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C498826:nilotinib
keywords: Imatinib; Stevens–Johnson syndrome; rash